Phenylketonuria (PKU) Treatment Agents

Phenylketonuria (PKU) treatment agents are a specialized therapeutic group of metabolic drugs designed to manage hyperphenylalaninemia in patients with phenylketonuria These agents function either by enhancing residual phenylalanine hydroxylase activity through synthetic or precursor cofactor substitution, or by providing enzymatic substitution using recombinant phenylalanine ammonia lyase to directly metabolize phenylalanine into harmless metabolites Consequently, these agents are indicated spe...

These agents function either by enhancing residual phenylalanine hydroxylase activity through synthetic or precursor cofactor substitution, or by providing enzymatic substitution using recombinant phenylalanine ammonia lyase to directly metabolize phenylalanine into harmless metabolites Their principal therapeutic role is to lower toxic blood phenylalanine concentrations, thereby preventing irreversible neurocognitive impairment, developmental delays, and psychiatric complications

These agents function either by enhancing residual phenylalanine hydroxylase activity through synthetic or precursor cofactor substitution, or by providing enzymatic substitution using recombinant phenylalanine ammonia lyase to directly metabolize phenylalanine into harmless metabolites

Their principal therapeutic role is to lower toxic blood phenylalanine concentrations, thereby preventing irreversible neurocognitive impairment, developmental delays, and psychiatric complications

Their principal therapeutic role is to lower toxic blood phenylalanine concentrations, thereby preventing irreversible neurocognitive impairment, developmental delays, and psychiatric complications

Consequently, these agents are indicated specifically for pediatric and adult populations diagnosed with phenylketonuria, typically in conjunction with dietary phenylalanine restriction